1,000
Participants
Start Date
June 30, 2019
Primary Completion Date
November 30, 2021
Study Completion Date
November 30, 2021
Adalimumab
Administered as specified in the treatment arm
Research Site, Bruges
Research Site, Brussels
Research Site, Genk
Research Site, Ghent
Research Site, Herentals
Research Site, Kortrijk
Research Site, Liège
Research Site, Sijsele
Research Site, Turnhout
Research Site, Berlin
Research Site, Bruchhausen-Vilsen
Research Site, Burghausen
Research Site, Dresden
Research Site, Elmshorn
Research Site, Erfurt
Research Site, Halle
Research Site, Hamburg
Research Site, Hamm
Research Site, Heidelberg
Research Site, Magdeburg
Research Site, Munich
Research Site, München
Research Site, Münster
Research Site, Oldenburg
Research Site, Ratingen
Research Site, Dublin
Research Site, Ancona
Research Site, Bari
Research Site, Florence
Research Site, Foggia
Research Site, Milan
Research Site, Modena
Research Site, Pavia
Research Site, San Giovanni Rotondo
Research Site, Siena
Research Site, Varese
Research Site, Almería
Research Site, Badajoz
Research Site, Donostia / San Sebastian
Research Site, Granada
Research Site, Mérida
Research Site, Sant Joan Despí
Research Site, Seville
Research Site, Terrassa
Research Site, Valladolid
Research Site, Ashford
Research Site, Bath
Research Site, Belfast
Research Site, Cambridge
Research Site, Kettering
Research Site, Luton
Research Site, Norwich
Research Site, Nottingham
Research Site, Sussex
Lead Sponsor
Biogen
INDUSTRY